Case Report

Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Guérin therapy

Sami Obaid, Alexander G. Weil, Ralph Rahme, Cathy Gendron, Daniel Shedid

Division of Neurosurgery, Hôpital Notre-Dame du CHUM, University of Montreal, Montreal, QC, Canada, 
Service of Neurosurgery, Centre Hospitalier Régional de Trois-Rivières, University of Montreal, Montreal, QC, Canada

E-mail: Sami Obaid - sami.obaid@mail.mcgill.ca; Alexander G. Weil - alexander.weil@umontreal.ca; Ralph Rahme - rrahme@waln.org; 
Cathy Gendron - cathy.gendron@hotmail.com; *Daniel Shedid - danielshedid@gmail.com
*Corresponding author

Received: 26 August 11 Accepted: 23 September 11 Published: 14 November 11

Access this article online
Website: www.surgicalneurologyint.com
DOI: 10.4103/2152-7806.89879
Quick Response Code:

Abstract

Background: Intravesical instillations of live-attenuated Bacillus Calmette-Guérin (BCG) are a well-known and effective method for prevention and treatment of bladder carcinoma and carcinoma in situ. Although considered a safe procedure with rare side effects, local and systemic complications may occur. While long bone osteomyelitis has been well described, very few reports of BCG spondylodiscitis exist in the literature.

Case Description: A 67-year-old man developed low back pain, anorexia, and weight loss 11 months after a 6-week course of intravesical BCG instillations for the treatment of bladder carcinoma in situ. Imaging studies revealed L1-L2 spondylodiscitis with epidural and bilateral psoas abscesses. Tissue cultures obtained by percutaneous computed tomography-guided aspiration were positive for Mycobacterium bovis. Despite triple antituberculous therapy (isoniazid, rifampin, and ethambutol), clinical and radiological progression occurred. Therefore, L1 and L2 corpectomies with extensive debridement were performed, followed by 360° anterior-posterior instrumented fusion. After 20 months of follow-up, the patient remains asymptomatic and recurrence-free.

Conclusion: Mycobacterium bovis spondylodiscitis is a rare complication of intravesical BCG therapy. Although medical therapy with antituberculous agents is the first-line treatment, surgical decompression, debridement, and stabilization may be necessary in refractory cases.

Key Words: Bacillus Calmette-Guérin, osteomyelitis, spondylodiscitis, tuberculosis

INTRODUCTION

Intravesical instillations of live-attenuated Bacillus Calmette-Guérin (BCG) are a well-known and effective method for prevention and treatment of bladder carcinoma and carcinoma in situ (CIS). Although considered a safe procedure with rare side effects, local and systemic complications may occur.[16,29] While long bone osteomyelitis has been well described, very few reports of BCG spondylodiscitis exist in the literature.[12,47,14,15,17-19,21,24,27] We report a rare case of lumbar Mycobacterium bovis osteomyelitis following...
intravesical BCG immunotherapy, which progressed under triple antituberculous therapy and warranted surgical decompression, debridement, and stabilization.

**CASE REPORT**

A 67-year-old man presented with a 5-month history of incapacitating low back pain (LBP), anorexia, and a 5-kg weight loss. Eleven months earlier, he had undergone a 6-week course of intravesical BCG instillation for superficial transitional cell CIS of the bladder. Physical examination revealed tenderness to palpation of the upper lumbar spine, but neurological examination was unremarkable. A complete blood workup was normal, including normal white blood cell count and normal erythrocyte sedimentation rate. Blood cultures and a tuberculin skin test were also negative. Computed Tomography (CT) and magnetic resonance imaging (MRI) of the lumbosacral spine revealed L1-L2 spondylodiscitis with a small, noncompressive anterior epidural collection and bilateral psoas muscle abscesses [Figure 1]. Percutaneous CT-guided drainage of the psoas abscesses was performed and aspirate cultures revealed *M. bovis*. The patient was treated conservatively using a thoracolumbar corset and triple antituberculous therapy (isoniazid, rifampin, and ethambutol).

Three months later, the patient exhibited worsening of his LBP with new-onset pain and mild weakness (4/5) in the right L2 distribution. Repeat CT and MRI [Figure 2] revealed progression of the spondylodiscitis with marked expansion of the anterior epidural abscess and compression of the cauda equina. Given the latter findings, surgical decompression, debridement, and stabilization were indicated. Through an anterior thoracoabdominal approach, L1 and L2 corpectomies with extensive debridement were performed, followed by T12-L3 instrumented fusion using a cadaveric femoral strut allograft [Figure 3a]. Following this first stage, a minimally invasive posterior T11-L4 instrumentation using percutaneously placed pedicle screws was performed to supplement the ventral construct [Figure 3b].

Postoperatively, the patient had an uneventful recovery with a complete resolution of his LBP and motor deficit. Antituberculous therapy was continued for a total of 9 months. After 20 months of follow-up, he
remains asymptomatic with no evidence of infection or tumor recurrence. Radiographic imaging demonstrated satisfactory alignment [Figures 3c and 3d].

**DISCUSSION**

The BCG vaccine was initially used in 1921 to prevent infection from tuberculosis. It is a live-attenuated strain of *M. bovis*, a component of the *Mycobacterium tuberculosis* complex. Since its introduction in 1976, intravesical BCG immunotherapy has been shown to be an effective therapy for preventing and treating superficial transitional cell bladder carcinoma and CIS. It eradicates bladder cancer through its inherent antineoplastic properties and local immune response. Although generally safe, serious side effects may occur in less than 5% of patients. Most serious adverse effects result from a systemic granulomatous infection with the BCG strain. Osteitis is rare following BCG immunization, occurring in less than 37 per 100,000 cases and its occurrence following intravesical BCG is exceptional. Only 13 cases of vertebral osteomyelitis resulting from intravesical BCG instillations have been previously reported in the literature [1,2,4,7,14,15,17-19,21,24,27] [Table 1]. In half of these cases, the infection showed good response to antituberculous therapy. Our case highlights that the infectious process may progress despite a three-drug regimen including isoniazid, rifampin, and ethambutol.

All previous cases of spinal BCG osteomyelitis secondary to intravesical BCG therapy have occurred at the thoracolumbar spine in elderly men (mean 79 years, range 66–90 years). Vertebral osteomyelitis in these patients is thought to result from hematogenous dissemination of BCG infection.[10,11,15,17,29] Although an immunity-mediated hypersensitivity reaction could theoretically underlie the granulomatous inflammatory response in the spine, identification of *M. bovis* in all cases (including our case) strongly suggests an actual dissemination of the bacillus from the bladder to the spine. Vascular dissemination and large-vessel mycotic vasculitis have been described following intravesical BCG immunotherapy, lending further support to hematogenous spread as a pathogenetic mechanism.[22] Injury to the bladder endothelium probably constitutes the first step for this hematogenous spread, which can occur as a result of several factors, including traumatic bladder catheterization, bladder injury during instillation, concurrent severe cystitis, bladder outlet obstruction, pelvic radiation, transurethral tumor resection, and prostate biopsy. The BCG infection likely spreads through Batson’s plexus, a network of valveless veins that connect the deep pelvic veins to the internal vertebral venous plexuses, which may explain its predilection for the thoracolumbar spine.[9]

**Table 1: A summary of reported cases of vertebral osteomyelitis/discitis following intravesical Bacillus Calmette-Guérin instillations**

| Reference                  | Age/ Sex | Time to onset | Clinical presentation                  | Level and type of spinal infection                      | Antimicrobial therapy | Surgery                                               | Outcome                                      |
|----------------------------|----------|---------------|---------------------------------------|--------------------------------------------------------|-----------------------|-------------------------------------------------------|---------------------------------------------|
| Katz et al.[15]            | 67/M     | 16 months     | LBP, buttock/thigh pain, right L5 and S1 radiculopathies, anorexia | L4–L5 spondylodiscitis                                  | INH + RIF + EMB       | L4–S1 laminotomies and L4–L5 discectomy, anterior spinal decompression and L3–L5 fusion using fibular bone graft | No long-term follow-up                      |
| Fishman et al.[7]          | 90/M     | 4 weeks       | LBP                                   | T11–T12 osteomyelitis                                  | INH + RIF + EMB       | Open surgical biopsy                                   | Not specified                               |
| Civen et al.[16]           | 81/M     | 7 months      | LBP, weight loss                      | T12–L1 spondylodiscitis, epidural abscess              | INH + Rif x 12 months | Open surgical biopsy, Harrington rods for spinal stabilization | Asymptomatic at 1 year                      |
| Sugita et al.[27]          | 71/M     | 2 months      | LBP                                   | T7 spondylitis                                        | INH + RIF + SM        | Anterior spinal fusion                                 | Not specified                               |
| Morgan and Iseman[19]      | 77/M     | 2 weeks       | LBP, weight loss, kyphotic deformity   | T11–L1 osteomyelitis, epidural soft tissue mass        | INH + RIF + EMB × 9 months, then INH + Rif × 6 months  | Surgical decompression, anterior and posterior spinal fusion | “Functional” at 1 year                     |
| Rozenblit et al[28]        | 76/M     | 6 years       | LBP, right leg pain, weight loss       | L4 osteomyelitis                                       | INH + Rif + EMB + ciprofloxacin | Percutaneous aspiration of prevertebral collection | Asymptomatic at 8 months, died 15 months later from myocardial infarction |
**Table 1: Contd...**

| Reference       | Age/Sex | Time to onset | Clinical presentation | Level and type of spinal infection | Antimicrobial therapy | Surgery                        | Outcome                                   |
|-----------------|---------|---------------|-----------------------|------------------------------------|-----------------------|---------------------------------|-------------------------------------------|
| Aljada et al. [2] | 79/M    | 2.5 years     | LBP, left hip pain, left lower extremity weakness | L3 osteomyelitis                   | INH + RIF × 12 months  | Decompressive laminectomy       | Persistent leg weakness at 1 year         |
| Abu-Nader [1]    | 76/M    | 7 years       | LBP, anorexia, weight loss, bilateral lower extremity weakness, paresthesias | T6–T7 spondylodiscitis            | INH + RIF + EMB × 12 months | Percutaneous biopsy of disc space | Symptoms improved                         |
| Nikaido et al. [19] | 86/M    | 2 years       | LBP                   | T12–L1 spondylodiscitis            | INH + RIF + EMB       | Percutaneous biopsy of disc space | Remission of symptoms at 1 month, died later of heart disease |
| Mavrogenis et al. [17] | 72/M    | 11 years      | LBP, leg pain, L2–L5 radiculopathies, anorexia, weight loss | L3–L4 spondylodiscitis, L3–L5 epidural soft tissue mass with anterior dural sac compression | INH + RIF + EMB × 12 months | Wide L3 and L4 decompressive laminectomies, L2–L5 posterior instrumented spinal fusion | Pain-free at 18 months                   |
| Patel et al. [21] | 66/M    | 5 months      | LBP                   | T10–T11 spondylodiscitis, T10–T11 epidural soft tissue mass with anterior cord compression | INH + RIF + EMB planned for 12 months | Percutaneous biopsy of the right T10 pedicle | Symptoms improved at 3-month follow-up |
| Josephson et al. [14] | 75/M    | 6 months      | LBP, generalized weakness, depression | L1–L2 spondulodiscitis, L1–L3 epidural soft tissue mass | INH + RIF × 12 months | Percutaneous aspiration          | No long-term follow-up                   |
| Colebatch et al. [5] | 67/M    | 2 years       | LBP                   | L4–L5 discitis                     | INH + RIF + EMB + PZA × 2 months, then INH + RIF × 5 months | Percutaneous disc space aspiration | Significant symptomatic improvement at 2 months, no long-term follow-up |
| Present case     | 67/M    | 4.5 months    | LBP, anorexia, weight loss | L1–L2 osteomyelitis, anterior epidural abscess | INH + RIF + EMB × 9 months | Percutaneous drainage of psoas abscesses, L1 and L2 corpectomies with femoral strut grafting and T12–L3 instrumented fusion, minimally invasive T11–L4 posterior instrumentation | Asymptomatic and disease-free at 20 months |

M: Male, LBP: Low back pain, INH: Isoniazid, RIF: Rifampin, EMB: Ethambutol, SM: Streptomycin, PZA: Pyrazinamide

An immunocompromised state may also contribute to the infection, thus accounting for its occurrence in the elderly population. [1]

Clinically, BCG spondylodiscitis typically presents with LBP and constitutional symptoms. Patients may also exhibit neurological deficits and spinal instability or deformity. The infection is commonly associated with psoas abscesses and occasionally with an epidural abscess. [14] The delay from intravesical BCG immunotherapy to symptom onset is highly variable, with patients developing symptoms anywhere between 2 weeks and 11 years (mean 31 months) following treatment. [6] The persistence of BCG bacilli in the urinary tract for prolonged periods
of time may account for the long latency period before spinal infection in some patients.\textsuperscript{[5,30]}

M. bovis infection should be suspected whenever primary spondylodiscitis occurs in a patient with a recent or remote history of BCG immunotherapy. The tuberculin skin test is not very useful in this setting because most patients are elderly and demonstrate anergy to the test.\textsuperscript{[1]}

Tissue must be obtained from the site of infection, and Ziehl-Neelsen staining should be performed to look for acid-fast bacilli. Cultures usually take several days before revealing Mycobacterium. Polymerase chain reaction and advanced molecular typing techniques will allow identification of M. bovis.\textsuperscript{[8,12,15,28,31]}

Antimicrobial therapy has been shown to be effective in the treatment of systemic manifestations following intravesical BCG therapy.\textsuperscript{[23]} Although there is no definitive consensus on the treatment regimen, most authors have used isoniazid and rifampin in combination as first-line agents, often with a second-line agent such as ethambutol.\textsuperscript{[1,2,4,7,14,17-21,24,27]} Subsequent BCG instillations should also be withheld.\textsuperscript{[10]} Using this treatment strategy, 6 of the 12 previous cases with sufficient treatment and follow-up details showed good response to medical therapy.\textsuperscript{[1,5,7,19,21,24]} Three cases progressed after initial medical therapy, requiring surgical decompression and fusion.\textsuperscript{[17,18,27]} In two other cases, surgical intervention was necessary at the time of diagnosis to decompress and/or stabilize the spine. One of these patients had a good outcome,\textsuperscript{[4]} while the other one did not.\textsuperscript{[2]} The last patient required a second surgical intervention for disease progression despite initial medical and surgical therapy.\textsuperscript{[15]} We report another case of disease progression under antituberculous therapy, resulting in pain and neurological deficit. Following surgical decompression, debridement, and fusion, the patient eventually had a favorable outcome and remains infection-free after 20 months of follow-up.

**CONCLUSION**

M. bovis spondylodiscitis may occur from months to years following intravesical BCG immunotherapy. This diagnosis should be suspected whenever primary spondylodiscitis occurs in a patient with a recent or remote history of BCG immunotherapy, particularly when the patient is elderly and the thoracolumbar spine is affected. The infection may progress despite appropriate antituberculous therapy, which may result in pain, neurological deficit, and spinal instability or deformity. In such cases, surgical intervention is warranted to decompress and stabilize the spine and treat the infection.

**REFERENCES**

1. Abu-Nader R, Terell CL. Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical BCG use. Mayo Clin Proc 2002;77:393-7.
2. Aljada IS, Crane JK, Corriere N, Wagle DG, Amsterdam DJ. Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol 1999;37:2106-8.
3. Bowyer L, Hall RR, Reading J, Marsh MM. The persistence of bacille Calmette-Guérin in the bladder after intravesical treatment for bladder cancer. Br J Urol 1995;75:188-92.
4. Civen R, Berlin G, Panosian C. Vertebral osteomyelitis after intravesical administration of bacille Calmette-Guérin [letter]. Clin Infect Dis 1994;18:1013-4.
5. Colebatch AN, Mounce KE. Mycobacterium bovis discitis as a complication of intravesical Bacillus Calmette-Guérin therapy. J Clin Rheumatol 2010;16:74-5.
6. Durack C, Richter E, Basteck A, Rüsch-Gerdes S, Gerdes J, Jocham D, et al. The fate of bacillus Calmette-Guérin after intravesical instillation. J Urol 2001;165:1765-8.
7. Fishman JR, Walton DT, Flynn NM, Benson DR, deVere White RW. Tuberculous spondylitis as a complication of intravesical bacillus Calmette-Guérin therapy. J Urol 1993;149:584-7.
8. Floyd MM, Silcox VA, Jones WD Jr, Butler WR, Kilburn JO. Separation of Mycobacterium bovis BCG from Mycobacterium tuberculosis and Mycobacterium bovis by using high-performance liquid chromatography of mycolic acids. J Clin Microbiol 1992;30:1327-30.
9. Geldof AA. Models for cancer skeletal metastasis: a reappraisal of Batson's plexus. Anticancer Res 1997;17:1535-9.
10. Guerra CE, Betts RF, O'Keefe RJ, Shilling JW. Mycobacterium bovis osteomyelitis involving a hip arthroplasty after intravesical bacilcal Calmette-Guérin for bladder cancer. Clin Infect Dis 1998;27:639-40.
11. Hakim S, Heaney JA, Heintz T, Zwolak RW. Prostatic abscess following intravesical bacillus Calmette-Guérin for bladder cancer: A case report. J Urol 1993;150:188-9.
12. Hermans PW, van Soolingen D, Dale JW, Schuitema AR, McAdam RA, Catty D, et al. Insertion element IS986 from Mycobacterium tuberculosis: A useful tool for diagnosis and epidemiology of tuberculosis. J Clin Microbiol 1990;28:2051-8.
13. Jones WD Jr. Differentiation of known strains of BCG from isolates of mycobacterium bovis and Mycobacterium tuberculosis by using mycobacteriophage 33D. J Clin Microbiol 1975;1:391-2.
14. Josephson CB, Al-Azri S, Smyth DJ, Haase D, Johnston BL. A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer. Can J Infect Dis Med Microbiol 2010;21:e75-8.
15. Katz DS, Wogaker H, D’Esposito RF, Cunha BA. Mycobacterium bovis vertebral osteomyelitis and psoas abscess after intravesical BCG therapy for bladder carcinoma. Urology 1992;40:46-3.
16. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600.
17. Mayr Genis AF, Sakellariou VI, Tsiodras S, Papageorgopoulou PJ, Latre Mycobacterium bovis spondylitis after intravesical BCG therapy. J Bone Spine 2009;76:296-300.
18. Morgan MB, Iseman MD. Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical administration of bacilli Calmette-Guérin. Ann J Med 1996;100:372-3.
19. Nikaido T, Ishibashi K, Otani K, Yabuki S, Konno S, Mori S, et al. Mycobacterium bovis BCG vertebral osteomyelitis after intravesical BCG therapy: diagnosed by PCR-based genomic deletion analysis. J Clin Microbiol 2007;45:4085-7.
20. Palayew M, Briedis D, Libman M, Michel RP, Levy RD. Disseminated infection after intravesical BCG immunotherapy. Detection of organisms in pulmonary tissue. Chest 1993;103:307-9.
21. Patel AR, Sabanej E, Jones JS, Gordon SM, Ballin M, Ruggieri PM, et al. Bacillus Calmette-Guérin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder. Eur Urol 2010;58:934-7.
22. Prescott S, Jackson AM, Hawkyard SJ, Alexandrov AB, James K. Mechanisms of action of intravesical bacille Calmette-Guérin: Local immune mechanisms. Clin Infect Dis 2000;31 Suppl 3:S591-3.
23. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: Recommendations for side-effects management. Eur Urol 2000;37 Suppl 1:S33-6.
24. Rozenblit A, Wasserman E, Marin ML, Veith FJ, Cynamon J, Rozenblit G. Infected aortic aneurysm and vertebral osteomyelitis after intravesical bacillus Calmette-Guérin therapy. AJR Am J Roentgenol 1996;167:711-3.
25. Seelig MH, Oldenburg WA, Klingler PJ, Blute ML, Pairolero PC. Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: Case report. J Vasc Surg 1999;29:377-81.
26. Steg A, Leleu C, Debré B, Boccon-Gibod L, Sicard D. Systemic bacillus Calmette-Guérin infection, ‘BCGitis’, in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol 1989;16:161-4.
27. Sugita Y, Chokyu H, Gotoh A, Maeda H, Umez K, Nakano Y. Tuberculous spondylitis after intravesical BCG instillation: A case report. Nihon Hinyokika Gakkai Zasshi 1995;86:1493-6.
28. Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guérin disease after vaccination: Case report and review. Clin Infect Dis 1997;24:1139-46.
29. Ulstrup JC, Jeansson S, Wiker HG, Harboe M. Relationship of secretion pattern and MPB70 homology with osteoblast-specific factor 2 to osteitis following Mycobacterium bovis BCG vaccination. Infect Immun 1995;63:672-5.
30. Van der Meijden AP. Practical approaches to the prevention and treatment of adverse reactions to BCG. Eur Urol 1995;27 Suppl 1:S23-8.
31. Van Soolingen D, Hermans PW, de Haas PE, van Embden JD. Insertion element IS1081-associated restriction fragment length polymorphisms in Mycobacterium tuberculosis complex species: A reliable tool for recognizing Mycobacterium bovis BCG. J Clin Microbiol 1992;30:1772-7.
32. Yossepowitch O, Eggener SE, Bochner BH, Donat SM, Herr HW, Dalbagni G. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol 2006;176:482-5.